Needham starts coverage on Evommune; shares gain

EVMN•2026-08-26

Stock performance since debut

Evommune has lost over 18% since its debut in November last year.

Needham initiates Evommune with buy rating

Shares of drug developer Evommune rose 1.7% to $14.02 after Needham started coverage on the company with a buy rating and a $28 price target.

Needham said its rating was based on the company's "promising I&I pipeline, notably EVO301, an IL-18 inhibitor fusion protein, that has demonstrated proof-of-concept efficacy on par (or better) vs. current biologics for atopic dermatitis (AD)."

The firm added that the upcoming September readout of the phase 2b trial in AD could generate significant shareholder value.

Needham starts coverage on Evommune; shares gain

Stock performance since debut

Needham initiates Evommune with buy rating

Related News

Brilliant Earth highlights asset-light inventory model, omnichannel growth strategy in investor presentation

Beachbody targets retail expansion with P90X, Insanity supplement and energy drink rollout in 2H 2026, presentation shows

Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million

CFN Enterprises FY26 Q2 net loss widens to $1.48 million; net revenues rise to $48,598

Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares